Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

We are in the midst of tremendous changes in the IT industry as new technologies and new ideas are disrupting traditional business models, <keyword id="6354512" type="CITY" weightage="100" keywordseo="Infosys">Infosys</keyword>' non-executive chairman <keyword id="2912855" type="PERSON" weightage="100" keywordseo="R-Seshasayee">R. Seshasayee</keyword> said on Monday. 
 "Chief Executive, <keyword id="6369763" type="PERSON" weightage="100" keywordseo="Vishal-Sikka">Vishal Sikka</keyword> and his management team have articulated a clear strategy to exploit these emerging opportunities," he told investors at the company's 34th annual general meeting. Seshasayee, 67, who took over the top post on June 5 from K.V. Kamath, has been an independent director of the global software major since January 2011 and its audit committee chairman. 

	"The board fully supports the strategic direction taken by the new management and we are confident of desired outcomes in the coming years," Seshasayee said in his first address to about 1,000 investors at a college auditorium in the city. 
	 
	 

	Acknowledging the efforts of the 1.76-lakh employees in shaping and growing the $8.7-billion company, the chairman said their dedication, hard work and sense of values had differentiated the company from others. 
	 
	 

	Noting that 2014-15 was a landmark year for the outsourcing firm during which three of the seven co-founders bid farewell and Sikka became the first non-founder executive, he said their vision, selfless efforts and fundamental values to build an institution had become the country's pride. 
 

	"The board of this company was chaired by two iconic leaders - co-founder N.R. Narayana Murthy and Kamath, who had set very high benchmarks in corporate governance and shareholder value creation," he .. 

	Kamath stepped down from the top post following his nomination as president of the $50-billion BRICS' development bank at Shanghai, 
 

	"Kamath has been a great source of guidance to all of on the board, bringing clarity of purpose and speed in execution, which helped in steering the troubled company through a time of change," Seshesayee noted. 
 Besides, Murthy, who was chairman, vice-chairman <keyword id="2913155" type="UNKNOWN" weightage="40" keywordseo="S-Gopalakrishnan">S.Gopalakrishnan</keyword> and chief executive S.D. Shibulal were the three co-founders who relinquished their executive posts in October and July last fiscal. The other four are <keyword id="44604" type="PERSON" weightage="60" keywordseo="Nandan-Nilekani">Nandan Nilekani</keyword>, N.S. Raghavan, K. Dinesh and <keyword id="336044" type="PERSON" weightage="40" keywordseo="Ashok-Arora">Ashok Arora</keyword>. 

	Though Raghavan retired in 2000 as joint managing director, and Arora, who was on the board till 1989, left for the US later, four co-founders steered the company from a $100 million to $8.7-billion IT behemoth as successive chief executives, with Shibulal being the last. 
 Nilekani, who was chief executive from 2002-07, quit the company as co-chairman in 2009 on becoming chairman of the <keyword id="86474" type="ORGANIZATION" weightage="40" keywordseo="Unique-Identification-Authority-of-India">Unique Identification Authority of India</keyword> ( UIDAI), which issues Aadhaar card to citizens. 

	Dinesh retired in 2011 as the company's head of quality, information systems and the communication design group. 

	 
	 
	(image credits: infosys)

2014-15 landmark year for Infosys: R. Seshasayee

The Indian Council of Medical Research (<keyword id="6364396" type="General" weightage="20" keywordseo="icmr" source="Orion">ICMR</keyword>) has come up with the country's first Ethical Guidelines for the Application of Artificial Intelligence in Biomedical Research and <keyword id="6354525" type="General" weightage="100" keywordseo="healthcare" source="Orion">Healthcare</keyword> to provide an ethical framework for the development of <keyword id="6355999" type="General" weightage="20" keywordseo="ai" source="Orion">AI</keyword>-based tools which will benefit all stakeholders. According to a document drafted by the Department of Health Research and ICMR's Artificial Intelligence Cell, AI for health, to a large extent, depends on data obtained from human participants and invokes additional concerns related to potential biases, data handling, interpretation, autonomy, risk minimization, professional competence, data sharing, and confidentiality. "It is therefore imperative to have an ethical framework that addresses issues specific to AI for biomedical research and healthcare," the guidelines stated. The adoption of AI technology in healthcare is growing in India. However, AI as data-driven technology has many potential ethical challenges which include algorithmic transparency and explainability, clarity on liability, accountability and oversight, bias and discrimination, said ICMR Director General Dr Rajiv Behl. "The DHR-ICMR AI Cell has identified the need to develop these guiding ethical principles concerning artificial intelligence and machine learning-based tools. "These guidelines will provide the ethical framework for the development of AI-based tools which will benefit all stakeholders, including innovators, developers, patients, technologists, researchers, healthcare professionals, ethics committees, sponsors and funding agencies involved in research related to AI in biomedical research and healthcare," he said. NTAGI chief Dr N K Arora said the purpose of the guideline is to provide an ethical framework which can assist in the development, deployment, and adoption of AI-based solutions for biomedical research and healthcare delivery. The guidelines are intended for all stakeholders involved in research on artificial intelligence in healthcare, including creators, developers, technicians, researchers, clinicians, ethics committees, institutions, sponsors, and funding organizations. It includes separate sections addressing ethical principles for AI in health, guiding principles for stakeholders, the ethics review process, governance of artificial intelligence for healthcare and research, and the informed consent process involving human participants and their data. The guideline has been formulated after extensive discussions with subject experts, researchers and ethicists, said Dr Arora. The induction of AI into healthcare has the potential to be the solution for significant challenges like diagnosis and screening, therapeutics, preventive treatments, clinical decision-making, public health surveillance, complex data analysis, and predicting disease outcomes. This list is likely to grow in the future, the document said. The purpose of these guidelines is not to limit innovation or recommend any disease-specific diagnostic or therapeutic approach but to guide effective yet safe development, deployment and adoption of AI-based technologies in biomedical research and healthcare delivery, it said. These guidelines will be used by experts and ethics committees reviewing research proposals involving the use of AI-based tools and technologies. SEE ALSO: <a href="https://www.businessinsider.in/business/startups/news/ashneer-grovers-new-startup-crickpe-is-a-fantasy-sports-app-that-will-also-reward-cricketers/articleshow/98964195.cms">Ashneer Grover's new startup CrickPe is a fantasy sports app that will also reward cricketers</a> <a href="https://www.businessinsider.in/tech/news/you-will-soon-lose-your-legacy-blue-tick-on-twitter-heres-everything-you-need-to-know/articleshow/98960333.cms">You will soon lose your legacy blue tick on Twitter – here’s everything you need to know</a> <a href="https://www.businessinsider.in/tech/mobile/news/three-out-of-four-premium-smartphones-sold-in-2022-were-an-iphone/articleshow/98855033.cms">Three out of four premium smartphones sold in 2022 were an iPhone</a>

ICMR comes up with first ethical guidelines for application of AI in biomedical research, healthcare

The Health Ministry intends to roll out <keyword id="102327" type="General" weightage="100" keywordseo="hpv" source="Orion">HPV</keyword> vaccine against cervical cancer in the national immunisation programme for girls aged 9 to 14 years in June for which a global tender is likely to be floated in April, official sources have said. Serum Institute's made-in-India HPV vaccine "CERVAVAC" was launched by Union Home Minister <keyword id="6355521" type="General" weightage="50" keywordseo="amit-shah" source="Orion">Amit Shah</keyword> on January 24, in presence of the Pune-based firm's CEO <keyword id="383467" type="General" weightage="50" keywordseo="adar-poonawalla" source="Orion">Adar Poonawalla</keyword> and Prakash Kumar Singh, its Director-Government and Regulatory Affairs. "The ministry is likely to float in April a global tender for 16.02 crore doses of HPV vaccine, which will be supplied by 2026. Apart from domestic manufacturer <keyword id="95879" type="General" weightage="50" keywordseo="serum-institute-of-india" source="Orion">Serum Institute of India</keyword>, global vaccine manufacturer Merck is also likely to participate in the tender," an official source said. In July last year, <keyword id="3658" type="General" weightage="80" keywordseo="india" source="Orion">India</keyword>'s drug regulator granted market authorization to Serum Institute of India's indigenously developed HPV vaccine. It has also been cleared by government advisory panel National Technical Advisory Group on Immunisation (NTAGI) for use in the public health programme. Prakash Kumar Singh, on the sidelines of a South Asia meet on HPV last month, had said that the price of CERVAVAC will be affordable compared to the international HPV vaccine available in India. India, at present, is fully dependent on foreign manufacturers for HPV vaccines. Globally, three foreign firms manufacture HPV vaccines out of which two sell their doses in India. Each dose of the vaccine available in the market costs more than Rs 4,000, sources said. In September 2022, Poonawalla had said that each dose of its "CERVAVAC" vaccine would cost Rs 200 to Rs 400. India, which is home to about 16 per cent of the world's women, accounts for about a quarter of all cervical cancer incidences and nearly a third of global cervical cancer deaths. Indian women face a 1.6 per cent lifetime cumulative risk of developing cervical cancer and a one per cent cumulative death risk from cervical cancer, according to officials. Recent estimates state that every year almost 80,000 women develop cervical cancer and 35,000 die in India due to it. On what prevented India from introducing the HPV vaccine till now, NTAGI chief Dr N K Arora had said that the vaccine supply has been a limiting factor globally. Fortunately, over the last five years, the global supply of the HPV vaccine has been improving gradually. India has taken a lead in this direction. Serum Institute of India, one of the major Indian vaccine manufacturers, with support from the Centre's Department of Biotechnology has developed four valent HPV vaccine. The vaccine has received regulatory approval and cleared by NTAGI for use in public health programmes. "We are given to understand that three other Indian vaccine manufacturers are also in various stages of developing the HPV vaccine," an official had said.

Govt likely to float global tender for HPV vaccine in April; Merck, Serum Institute may participate

2020 IPL auction will see these 332 players trying their luck under the hammer

FED VICE CHAIR FISCHER: 'We should also expect spillovers when monetary policy is tightened'

You Searched For "n k arora" and got 5 results

2014-15 landmark year for Infosys: R. Seshasayee

BI India Bureau

ICMR comes up with first ethical guidelines for application of AI in biomedical research, healthcare

PTI

Govt likely to float global tender for HPV vaccine in April; Merck, Serum Institute may participate

PTI

2020 IPL auction will see these 332 players trying their luck under the hammer

BI India Bureau

FED VICE CHAIR FISCHER: 'We should also expect spillovers when monetary policy is tightened'

Sam Ro

Popular Keywords

Buying Guides